Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Voulgarelis, P. Ziakas, A. Papageorgiou, Evangelia Baimpa, A. Tzioufas, H. Moutsopoulos (2012)
Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren SyndromeMedicine, 91
Owen Griffith, D. Stuehr (1995)
Nitric oxide synthases: properties and catalytic mechanism.Annual review of physiology, 57
H. Moutsopoulos (2014)
Sjögren's syndrome: a forty-year scientific journey.Journal of autoimmunity, 51
Qin Wang, Y. Mao-Draayer (2015)
Interferon beta (IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathwayNeural Regeneration Research, 10
P. Youinou, J. Pers (2015)
Primary Sjögren's syndrome at a glance today.Joint, bone, spine : revue du rhumatisme, 82 2
F. Skopouli, U. Dafni, J. Ioannidis, H. Moutsopoulos (2000)
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome.Seminars in arthritis and rheumatism, 29 5
A. Theofilopoulos, R. Baccala, B. Beutler, D. Kono (2005)
Type I interferons (alpha/beta) in immunity and autoimmunity.Annual review of immunology, 23
T. Tarpley, L. Anderson, C. White (1974)
Minor salivary gland involvement in Sjögren's syndrome.Oral surgery, oral medicine, and oral pathology, 37 1
C. Touil-Boukoffa, Brigitte Bauvois, J. Sancéau, Boussad Hamrioui, Juana Wietzerbin (1998)
Production of nitric oxide (NO) in human hydatidosis: relationship between nitrite production and interferon-gamma levels.Biochimie, 80 8-9
Ajay Wanchu, Madhu Khullar, Archana Sud, Pradeep Bambery (2000)
Elevated Nitric Oxide Production in Patients with Primary Sjögren’s SyndromeClinical Rheumatology, 19
L. Kasper, A. Reder (2014)
Immunomodulatory activity of interferon-betaAnnals of Clinical and Translational Neurology, 1
H. Belguendouz, D. Messaoudène, K. Lahmar, L. Ahmedi, Osama Medjeber, D. Hartani, O. Lahlou-Boukoffa, C. Touil-Boukoffa (2011)
Interferon-γ and nitric oxide production during Behçet uveitis: immunomodulatory effect of interleukin-10.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 31 9
S. Dhib-Jalbut, S. Marks (2010)
Interferon-β mechanisms of action in multiple sclerosisNeurology, 74
A. Noronha, A. Toscas, M. Jensen (1993)
Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis.Journal of neuroimmunology, 46 1-2
Susana Inogés, Juana Merino, E. Bandrés, P. Castro, M. Subirá, A. Sánchez-Ibarrola (1999)
Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patientsClinical & Experimental Immunology, 115
S. Iyer, G. Cheng (2012)
Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.Critical reviews in immunology, 32 1
Dilek Uğar-Cankal, N. Ozmeric (2006)
A multifaceted molecule, nitric oxide in oral and periodontal diseases.Clinica chimica acta; international journal of clinical chemistry, 366 1-2
A. Arroul-Lammali, F. Rahal, Radia Chetouane, Z. Djeraba, O. Medjeber, A. Ladjouze-Rezig, C. Touil-Boukoffa (2017)
Ex vivo all-trans retinoic acid modulates NO production and regulates IL-6 effect during rheumatoid arthritis: a study in Algerian patientsImmunopharmacology and Immunotoxicology, 39
J. Routsias, J. Goules, G. Charalampakis, S. Tzima, A. Papageorgiou, M. Voulgarelis (2013)
Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment.Seminars in arthritis and rheumatism, 43 2
A. Bon, G. Schiavoni, G. D'agostino, I. Gresser, F. Belardelli, D. Tough (2001)
Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.Immunity, 14 4
A. Noronha, A. Toscas, M. Jensen (1993)
Interferon β decreases T cell activation and interferon γ production in multiple sclerosisJournal of Neuroimmunology, 46
N. Boivin, J. Baillargeon, Prenitha Doss, A. Roy, Manu Rangachari (2015)
Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting CellsPLoS ONE, 10
Mohamed El-behi, A. Rostami, B. Ciric (2010)
Current Views on the Roles of Th1 and Th17 Cells in Experimental Autoimmune EncephalomyelitisJournal of Neuroimmune Pharmacology, 5
Ø. Torkildsen, Ø. Torkildsen, K. Myhr, K. Myhr, L. Bø, L. Bø (2015)
Disease-modifying treatments for multiple sclerosis – a review of approved medicationsEuropean Journal of Neurology, 23
M. Colonna, G. Trinchieri, Yong‐jun Liu (2004)
Plasmacytoid dendritic cells in immunityNature Immunology, 5
F. Ferro, E. Marcucci, M. Orlandi, C. Baldini, E. Bartoloni-Bocci (2017)
One year in review 2017: primary Sjögren's syndrome.Clinical and experimental rheumatology, 35 2
J. Ioannidis, V. Vassiliou, H. Moutsopoulos (2002)
Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome.Arthritis and rheumatism, 46 3
G. Luca, A. Lugaresi, C. Iarlori, F. Marzoli, A. Uncini, D. Gambi (1998)
Interferon beta normalizes suppressor cell function in dysimmune neuropathiesJournal of Neuroimmunology, 82
Sarah Benchabane, H. Belguendouz, N. Behairi, A. Arroul-Lammali, A. Boudjelida, P. Youinou, C. Touil-Boukoffa (2018)
Cardamonin inhibits pro-inflammatory cytokine production and suppresses NO pathway in PBMCs from patients with primary Sjögren’s syndromeImmunopharmacology and Immunotoxicology, 40
Manu Rangachari, Chen Zhu, K. Sakuishi, S. Xiao, J. Karman, A. Chen, M. Angin, A. Wakeham, E. Greenfield, R. Sobel, H. Okada, P. Mckinnon, T. Mak, M. Addo, A. Anderson, V. Kuchroo (2012)
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustionNature Medicine, 18
Chen Zhu, A. Anderson, A. Schubart, H. Xiong, J. Imitola, S. Khoury, X. Zheng, T. Strom, V. Kuchroo (2005)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunityNature Immunology, 6
M. Belkhelfa, H. Rafa, O. Medjeber, A. Arroul-Lammali, N. Behairi, M. Abada-Bendib, M. Makrelouf, S. Belarbi, A. Masmoudi, M. Tazir, C. Touil-Boukoffa (2014)
IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 34 11
H. Rafa, M. Amri, H. Saoula, M. Belkhelfa, Osama Medjeber, A. Boutaleb, Saida Aftis, M. Nakmouche, C. Touil-Boukoffa (2010)
Involvement of interferon-γ in bowel disease pathogenesis by nitric oxide pathway: a study in Algerian patients.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 30 9
C. Mavragani, H. Moutsopoulos (2010)
The geoepidemiology of Sjögren's syndrome.Autoimmunity reviews, 9 5
C. Vitali, S. Bombardieri, R. Jonsson, H. Moutsopoulos, E. Alexander, S. Carsons, T. Daniels, P. Fox, Robert Fox, S. Kassan, S. Pillemer, N. Talal, M. Weisman (2002)
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 61
Y. Konttinen, L. Platts, S. Tuominen, K. Eklund, N. Santavirta, J. Törnwall, T. Sorsa, M. Hukkanen, J. Polak (1997)
Role of nitric oxide in Sjögren's syndrome.Arthritis and rheumatism, 40 5
Yan Wang, Ning Wang, Biao Cai, Guang-Yun Wang, Jing Li, Xing-Xing Piao (2015)
In vitro model of the blood-brain barrier established by co-culture of primary cerebral microvascular endothelial and astrocyte cellsNeural Regeneration Research, 10
OW Griffith, DJ Stuehr (1995)
NO synthases: properties and catalytic mechanismAnnu Rev Physiol, 57
Interferons, A. Theofilopoulos, R. Baccala, B. Beutler, D. Kono (2005)
TYPE I INTERFERONS (/) IN IMMUNITY AND AUTOIMMUNITY
Sarah Benchabane, A. Boudjelida, R. Toumi, H. Belguendouz, P. Youinou, C. Touil-Boukoffa (2016)
A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren’s syndromeInternational Journal of Immunopathology and Pharmacology, 29
T. Korn, M. Mitsdoerffer, Andrew Croxford, A. Awasthi, V. Dardalhon, George Galileos, P. Vollmar, Gretta Stritesky, M. Kaplan, A. Waisman, V. Kuchroo, M. Oukka (2008)
IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cellsProceedings of the National Academy of Sciences, 105
Sourour Zidi, F. Bédiar-Boulaneb, H. Belguendouz, M. Belkhelfa, Osama Medjeber, O. Laouar, C. Henchiri, C. Touil-Boukoffa (2017)
Local pro-inflammatory cytokine and nitric oxide responses are elevated in patients with pterygiumInternational Journal of Immunopathology and Pharmacology, 30
A. Reder, S. Velichko, K. Yamaguchi, K. Hamamcioğlu, Karin Ku, J. Beekman, T. Wagner, H. Perez, H. Salamon, E. Croze (2008)
IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 28 5
YT Konttinen, LA Platts, S Tuominen (1997)
Role of NO in Sjogren’s syndromeArthritis Rheum, 40
P. Youinou, A. Saraux, J. Pers (2012)
B-lymphocytes govern the pathogenesis of Sjögren's syndrome.Current pharmaceutical biotechnology, 13 10
Background Primary Sjögren’s syndrome (pSS) represents a chronic, systemic autoimmune disorder, characterized by lymphocytic infiltration of exocrine glands, inducing compromised secretory function and tissue destruction. Increasing evidence had revealed that inflammatory mediators, such as nitric oxide (NO) and pro-inflammatory cytokines, are critical in the development and perpetuation of pSS systemic manifestations. In our current study, we aimed to investigate the ex vivo immunomodulatory effect of interferon (IFN)-β on iNOS expression, as well as on pro-inflammatory (tumor necrosis fac - tor (TNF)-α, interleukin (IL)-6) and immunoregulatory (IL-10) cytokine production. Furthermore, we examined potential associations between the influence of IFN-β treatment on NO production, and pSS clinical and serological manifestations. Methods In 41 pSS patients documented for their clinical and serological features, NO and cytokines levels were measured by the Griess method and enzyme-linked immunosorbent assay, respectively. Inducible nitric oxide synthase expression was analyzed by fluorescence immunostaining assay, using peripheral blood mononuclear cells (PBMCs) isolated from healthy controls and pSS patients. Results Our results revealed a strong down-modulating effect of IFN-β in the secretion of pro-inflammatory mediators including TNF-α, IL-6, and NO production. Interestingly, IFN-β exerts an increase in IL-10 levels. The most suppressive effect exerted by IFN-β on NO production was
Inflammopharmacology – Springer Journals
Published: Jun 4, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.